Drug intelligence / Profile preview

JW0202 + C2202

Development stage: Unknown
Lead developer: JW Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**JW0202 + C2202** refers to the combination of two small molecule drugs studied together for their pharmacokinetic and safety profile in healthy volunteers and evaluated as part of combination therapy in type 2 diabetes mellitus. JW0202 and C2202 are both investigational drugs developed by JW PHARMACEUTICAL with ongoing research into their efficacy and safety as adjuncts for patients with inadequate glycemic control.

Beyond the preview

Go deeper on JW0202 + C2202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JW0202 + C2202.

Explore the full profile